Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA. Elewski BE, et al. Among authors: williams da. J Am Acad Dermatol. 2018 Jan;78(1):90-99.e1. doi: 10.1016/j.jaad.2017.08.029. Epub 2017 Oct 6. J Am Acad Dermatol. 2018. PMID: 28993005 Free article. Clinical Trial.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Kimball AB, et al. Among authors: williams da. N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. N Engl J Med. 2016. PMID: 27518661 Free article. Clinical Trial.
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Zouboulis CC, et al. Among authors: williams da. J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2. doi: 10.1016/j.jaad.2018.05.040. Epub 2018 Jun 1. J Am Acad Dermatol. 2019. PMID: 29860040 Clinical Trial.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Reich K, et al. Among authors: williams da. Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Lancet. 2019. PMID: 31280967 Clinical Trial.
Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM. Papp KA, et al. Among authors: williams da. J Eur Acad Dermatol Venereol. 2014 Jun;28(6):790-8. doi: 10.1111/jdv.12177. Epub 2013 May 17. J Eur Acad Dermatol Venereol. 2014. PMID: 23679896 Clinical Trial.
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Strober BE, et al. Among authors: williams da. Br J Dermatol. 2011 Sep;165(3):661-8. doi: 10.1111/j.1365-2133.2011.10419.x. Epub 2011 Jul 28. Br J Dermatol. 2011. PMID: 21574984 Clinical Trial.
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Langley RG, et al. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61. doi: 10.1111/j.1468-3083.2012.04705.x. Epub 2012 Nov 16. J Eur Acad Dermatol Venereol. 2013. PMID: 23157612
1,228 results